NicOx (OTCMKTS:NICXF) Stock Rating Upgraded by ValuEngine

NicOx (OTCMKTS:NICXF) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday, ValuEngine reports.

Separately, Zacks Investment Research raised NicOx from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Tuesday, July 23rd.

NicOx stock traded down $0.07 during mid-day trading on Thursday, hitting $5.12. The company’s stock had a trading volume of 3,573 shares, compared to its average volume of 3,695. The company has a 50 day simple moving average of $5.56. NicOx has a one year low of $5.10 and a one year high of $9.68.

NicOx Company Profile

Nicox SA, an ophthalmic company, researches, develops, and markets therapies that target various ophthalmic conditions in France and internationally. The company's product pipeline includes VyzultaTM, an intraocular pressure-lowering treatment; and NCX 470, a nitric oxide (NO)-donating candidate to treat glaucoma, as well as stand-alone NO donors for specific applications in ophthalmic diseases.

See Also: Rule of 72

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for NicOx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NicOx and related companies with MarketBeat.com's FREE daily email newsletter.